 Shandra Knight
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 16 | 2025 | 664 | 1.870 |
Why?
| | Scleroderma, Systemic | 6 | 2024 | 123 | 1.130 |
Why?
| | Idiopathic Pulmonary Fibrosis | 7 | 2022 | 692 | 0.690 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2021 | 93 | 0.610 |
Why?
| | Mycobacterium kansasii | 3 | 2020 | 14 | 0.480 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2022 | 339 | 0.470 |
Why?
| | Mycobacterium abscessus | 3 | 2020 | 110 | 0.420 |
Why?
| | Societies, Medical | 6 | 2025 | 899 | 0.310 |
Why?
| | Lung | 11 | 2024 | 4106 | 0.300 |
Why?
| | Bacteriuria | 2 | 2019 | 12 | 0.300 |
Why?
| | Asymptomatic Infections | 2 | 2019 | 37 | 0.290 |
Why?
| | Injections | 2 | 2019 | 199 | 0.270 |
Why?
| | Administration, Intravenous | 2 | 2019 | 172 | 0.270 |
Why?
| | Drug Utilization | 2 | 2019 | 168 | 0.270 |
Why?
| | Pulmonary Fibrosis | 2 | 2022 | 395 | 0.260 |
Why?
| | Urinary Tract Infections | 2 | 2019 | 210 | 0.240 |
Why?
| | Disease Management | 3 | 2019 | 653 | 0.240 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 232 | 0.240 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2016 | 58 | 0.230 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 113 | 0.220 |
Why?
| | Outpatients | 2 | 2019 | 447 | 0.220 |
Why?
| | Biopsy | 7 | 2022 | 1082 | 0.220 |
Why?
| | Tracheostomy | 1 | 2025 | 142 | 0.200 |
Why?
| | Cross Infection | 2 | 2016 | 260 | 0.200 |
Why?
| | Tobacco Use Disorder | 1 | 2025 | 217 | 0.200 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 919 | 0.190 |
Why?
| | Indoles | 2 | 2024 | 507 | 0.190 |
Why?
| | Nicotine | 1 | 2025 | 331 | 0.190 |
Why?
| | Immunosuppressive Agents | 5 | 2024 | 838 | 0.180 |
Why?
| | Lymphocytes | 2 | 2020 | 376 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 440 | 0.170 |
Why?
| | Disease Progression | 6 | 2024 | 2864 | 0.170 |
Why?
| | Humans | 39 | 2025 | 145475 | 0.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 638 | 0.160 |
Why?
| | Hypercapnia | 1 | 2020 | 53 | 0.160 |
Why?
| | Bronchoscopy | 4 | 2022 | 227 | 0.150 |
Why?
| | Inhalation Exposure | 1 | 2020 | 103 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2022 | 237 | 0.150 |
Why?
| | Immunoglobulin G | 2 | 2021 | 892 | 0.150 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 62 | 0.150 |
Why?
| | Cyclophosphamide | 3 | 2024 | 270 | 0.140 |
Why?
| | Nontuberculous Mycobacteria | 4 | 2022 | 189 | 0.140 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2020 | 98 | 0.140 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2020 | 181 | 0.140 |
Why?
| | United States | 11 | 2025 | 16098 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 992 | 0.130 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1581 | 0.130 |
Why?
| | Home Care Services | 1 | 2020 | 284 | 0.130 |
Why?
| | Liver Diseases | 1 | 2020 | 305 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 740 | 0.120 |
Why?
| | Cardiomyopathies | 1 | 2020 | 335 | 0.120 |
Why?
| | Neurocognitive Disorders | 1 | 2016 | 33 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2020 | 425 | 0.120 |
Why?
| | Mycobacterium avium Complex | 3 | 2020 | 87 | 0.110 |
Why?
| | Anti-Bacterial Agents | 4 | 2019 | 1923 | 0.110 |
Why?
| | Lung Diseases | 1 | 2022 | 780 | 0.110 |
Why?
| | Quality of Life | 5 | 2024 | 3204 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2022 | 2769 | 0.100 |
Why?
| | Adult | 13 | 2022 | 40777 | 0.090 |
Why?
| | Rituximab | 2 | 2024 | 210 | 0.090 |
Why?
| | Influenza, Human | 1 | 2019 | 624 | 0.090 |
Why?
| | Antacids | 2 | 2022 | 16 | 0.090 |
Why?
| | Hypertension, Pulmonary | 2 | 2021 | 1957 | 0.090 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2016 | 302 | 0.090 |
Why?
| | Americas | 2 | 2019 | 27 | 0.070 |
Why?
| | Neutropenia | 2 | 2019 | 154 | 0.070 |
Why?
| | Drug Therapy | 2 | 2019 | 84 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 1797 | 0.070 |
Why?
| | Transplant Recipients | 2 | 2019 | 181 | 0.060 |
Why?
| | Societies | 2 | 2017 | 40 | 0.060 |
Why?
| | Antimicrobial Stewardship | 2 | 2019 | 130 | 0.060 |
Why?
| | Communicable Diseases | 2 | 2019 | 166 | 0.060 |
Why?
| | HIV Infections | 1 | 2022 | 3194 | 0.060 |
Why?
| | Bacteriological Techniques | 2 | 2016 | 66 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2016 | 77 | 0.060 |
Why?
| | Gene-Environment Interaction | 1 | 2025 | 180 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2187 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2023 | 46 | 0.050 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2025 | 110 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 120 | 0.050 |
Why?
| | Vital Capacity | 1 | 2024 | 292 | 0.050 |
Why?
| | Spirometry | 1 | 2023 | 233 | 0.050 |
Why?
| | Child | 4 | 2025 | 22707 | 0.050 |
Why?
| | Dyspnea | 1 | 2024 | 250 | 0.040 |
Why?
| | Prevalence | 2 | 2019 | 2865 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2023 | 544 | 0.040 |
Why?
| | Bronchial Provocation Tests | 1 | 2021 | 47 | 0.040 |
Why?
| | Bronchoalveolar Lavage | 1 | 2020 | 89 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
| | Prospective Studies | 2 | 2024 | 8057 | 0.040 |
Why?
| | Lymphadenopathy | 1 | 2020 | 8 | 0.040 |
Why?
| | Mediastinum | 1 | 2020 | 23 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 209 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 133 | 0.040 |
Why?
| | Hypercalcemia | 1 | 2020 | 22 | 0.040 |
Why?
| | Medical History Taking | 1 | 2020 | 117 | 0.040 |
Why?
| | Cryosurgery | 1 | 2020 | 46 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2020 | 85 | 0.040 |
Why?
| | Exhalation | 1 | 2020 | 29 | 0.040 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2020 | 63 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2020 | 151 | 0.040 |
Why?
| | Alkaline Phosphatase | 1 | 2020 | 144 | 0.040 |
Why?
| | Pulmonary Medicine | 1 | 2020 | 78 | 0.040 |
Why?
| | Eye Diseases | 1 | 2020 | 97 | 0.040 |
Why?
| | Patient Discharge | 1 | 2025 | 992 | 0.040 |
Why?
| | Endosonography | 1 | 2020 | 160 | 0.040 |
Why?
| | Chemoprevention | 1 | 2019 | 92 | 0.030 |
Why?
| | Latin America | 1 | 2018 | 96 | 0.030 |
Why?
| | Japan | 1 | 2018 | 149 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 343 | 0.030 |
Why?
| | Creatinine | 1 | 2020 | 515 | 0.030 |
Why?
| | Sarcoidosis | 1 | 2020 | 163 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3904 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6066 | 0.030 |
Why?
| | Europe | 1 | 2018 | 418 | 0.030 |
Why?
| | Eosinophils | 1 | 2020 | 316 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2020 | 503 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 647 | 0.030 |
Why?
| | Hemorrhage | 1 | 2022 | 822 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2378 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 825 | 0.030 |
Why?
| | Electrocardiography | 1 | 2020 | 665 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 484 | 0.030 |
Why?
| | Vitamin D | 1 | 2020 | 403 | 0.030 |
Why?
| | Caregivers | 1 | 2025 | 1073 | 0.030 |
Why?
| | Seasons | 1 | 2019 | 538 | 0.030 |
Why?
| | Pregnancy | 2 | 2019 | 7202 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2019 | 419 | 0.030 |
Why?
| | Hemodynamics | 1 | 2021 | 1118 | 0.030 |
Why?
| | Aged | 3 | 2020 | 26153 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 892 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 17291 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1808 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1747 | 0.030 |
Why?
| | Calcium | 1 | 2020 | 1190 | 0.030 |
Why?
| | Male | 4 | 2025 | 72843 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1508 | 0.020 |
Why?
| | Adolescent | 2 | 2025 | 22530 | 0.020 |
Why?
| | Female | 4 | 2025 | 78845 | 0.020 |
Why?
| | Infant | 1 | 2025 | 10077 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 10885 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11853 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 7123 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8333 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2016 | 11772 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 36215 | 0.010 |
Why?
|
|
Knight's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|